The present disclosure provides a compound of Formula (I): ##STR00001##
or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), therapeutic methods for treating inflammatory disease.

The present disclosure provides a compound of Formula (I): ##STR00001##
or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), therapeutic methods for treating inflammatory disease.

The present invention relates to pyrimidone compounds used as Lp-PLA.sub.2 inhibitors and pharmaceutical compositions thereof. The structure of the pyrimidone compounds is represented by general formula (I), wherein R.sub.1, R.sub.2, R.sub.3, X, Ar, Y and n are defined as in the specification and claims. The compounds of general formula (I) in the present invention, stereoisomers and pharmaceutically acceptable salts thereof can be used as Lp-PLA.sub.2 inhibitors for preventing, treating and/or ameliorating diseases associated with the activity of Lp-PLA.sub.2 enzyme.

##STR00001##

The present invention relates to pyrimidone compounds used as Lp-PLA.sub.2 inhibitors and pharmaceutical compositions thereof. The structure of the pyrimidone compounds is represented by general formula (I), wherein R.sub.1, R.sub.2, R.sub.3, X, Ar, Y and n are defined as in the specification and claims. The compounds of general formula (I) in the present invention, stereoisomers and pharmaceutically acceptable salts thereof can be used as Lp-PLA.sub.2 inhibitors for preventing, treating and/or ameliorating diseases associated with the activity of Lp-PLA.sub.2 enzyme.

##STR00001##

Provided are a nonaqueous electrolyte capable of providing a nonaqueous electrolyte energy storage device with reduced direct current resistance and an increased capacity retention ratio after charge-discharge cycles, a nonaqueous electrolyte energy storage device including such a nonaqueous electrolyte, and a method for producing such a nonaqueous electrolyte energy storage device. One mode of the present invention is a nonaqueous electrolyte for an energy storage device, containing an additive represented by the following Formula (1) or Formula (2). In Formula (1), R.sup.1 to R.sup.4 are each independently a hydrogen atom or a group represented by —NR.sup.a.sub.2, —OR.sup.a, —SR.sup.a, etc., with the proviso that at least one of R.sup.1 to R.sup.4 is a group represented by —OR.sup.a, —SR.sup.a, —COOR.sup.a, —COR.sup.a, —SO.sub.2R.sup.a, or —SO.sub.3R.sup.a. In Formula (2), R.sup.5 to R.sup.7 are each independently a hydrogen atom or a group represented by —NR.sup.b.sub.2, —OR.sup.b, or —SR.sup.b, with the proviso that at least one of R.sup.5 to R.sup.7 is a group represented by —SR.sup.b. ##STR00001##

Provided are a nonaqueous electrolyte capable of providing a nonaqueous electrolyte energy storage device with reduced direct current resistance and an increased capacity retention ratio after charge-discharge cycles, a nonaqueous electrolyte energy storage device including such a nonaqueous electrolyte, and a method for producing such a nonaqueous electrolyte energy storage device. One mode of the present invention is a nonaqueous electrolyte for an energy storage device, containing an additive represented by the following Formula (1) or Formula (2). In Formula (1), R.sup.1 to R.sup.4 are each independently a hydrogen atom or a group represented by —NR.sup.a.sub.2, —OR.sup.a, —SR.sup.a, etc., with the proviso that at least one of R.sup.1 to R.sup.4 is a group represented by —OR.sup.a, —SR.sup.a, —COOR.sup.a, —COR.sup.a, —SO.sub.2R.sup.a, or —SO.sub.3R.sup.a. In Formula (2), R.sup.5 to R.sup.7 are each independently a hydrogen atom or a group represented by —NR.sup.b.sub.2, —OR.sup.b, or —SR.sup.b, with the proviso that at least one of R.sup.5 to R.sup.7 is a group represented by —SR.sup.b. ##STR00001##

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.

Described herein are novel divalent nucleobases that each bind two nucleic acid strands, matched or mismatched when incorporated into a nucleic acid or nucleic acid analog backbone (a genetic recognition reagent, or genetic recognition reagent). In one embodiment, the genetic recognition reagent is a peptide nucleic acid (PNA) or gamma PNA (γPNA) oligomer. Uses of the divalent nucleobases and monomers and genetic recognition reagents containing the divalent nucleobases also are provided.

Described herein are novel divalent nucleobases that each bind two nucleic acid strands, matched or mismatched when incorporated into a nucleic acid or nucleic acid analog backbone (a genetic recognition reagent, or genetic recognition reagent). In one embodiment, the genetic recognition reagent is a peptide nucleic acid (PNA) or gamma PNA (γPNA) oligomer. Uses of the divalent nucleobases and monomers and genetic recognition reagents containing the divalent nucleobases also are provided.

Disclosed are small molecules against cereblon to enhance effector T cell function. Methodos of making thes molecules and methods of using them to treat various disease states are also disclosed.